Spero Therapeutics, Inc.

SPRO • Biotechnology

$1.22

▼ -0.00 (-0.38%)

Precio actual

ResultadosÚltimo reporte: 30 jun 2026

PERFIL EQUILIBRADONeutralConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Perfil mixto. La empresa no es necesariamente mala, pero la valoración, el crecimiento o el balance todavía no justifican una señal más fuerte.

Capitalización

$72.46M

Crecimiento

—

Flujo de caja

0/5

Tendencia

Negative

Evidencia

Márgenes estables o en mejora · 14.4%Crecimiento positivo de ingresos · 80.9%Múltiplo de ganancias razonable · 15.23Nivel de deuda manejable · 0.05Liquidez saludable · 7.59

Datos financieros hasta: 30 jun 2026, 12:00 a.m. UTCÚltima actualización de earnings: 30 jun 2026, 12:00 a.m. UTCÚltima actualización del perfil: 14 ago 2026, 12:28 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$1.22

Change-0.38%

Shares Out57.97M

Market Cap$72.46M

Enterprise Value$23.73M

52W Range1.08 - 3.08

Beta1.48

P/E4.28

P/S1.69

P/B1.64

P/FCF3.70

EV/Sales0.55

Price$1.22

Change-0.38%

Shares Out57.97M

Market Cap$72.46M

Enterprise Value$23.73M

52W Range1.08 - 3.08

Beta1.48

P/E4.28

P/S1.69

P/B1.64

P/FCF3.70

EV/Sales0.55

EV/EBITDA3.62

EV/FCF1.21

Earnings Yield23.37%

FCF Yield27.02%

Dividend Yield0.00%

Gross Margin100.00%

Oper. Margin-0.04%

Profit Margin14.38%

Debt/Eq0.05

Current Ratio7.59

Quick Ratio7.59

Volume1.28M

Avg Volume1.26M

EPS Surprise0.05

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

61/100

Fortaleza financiera

Deuda, caja, estabilidad

76/100

Potencial de crecimiento

Ingresos y expansión

95/100

Atractivo del precio

Barata o cara hoy

82/100

Por qué este puntaje▼

Márgenes estables o en mejora · 14.4%Crecimiento positivo de ingresos · 80.9%Múltiplo de ganancias razonable · 15.23Nivel de deuda manejable · 0.05Liquidez saludable · 7.59

Analyst view

Analyst sentiment and price target

SPRO

Analyst sentiment

Based on 13 analyst votes · 2026-10-20

65/100

Neutral

Bullish

Hold

Bearish

Resumen de la compañía

IPO: 11/2/2017

Industria: Biotechnology

P/B i: 1.64

Deuda / Patrimonio i: 0.05

Margen operativo: -0.04%

Margen neto: 14.38%

ROE i: -

ROIC: -

Salud financiera

Puntaje15 / 20

Deuda / Patrimonio: 0.05

Ratio corriente: 7.59

Ratio rápido: 7.59

Estado: Good

Transacciones internas

Actividad reciente de ejecutivos e insiders

Zack Debra

Transacción: 08/03/2026

OTRO

Cambio

Precio

Not reported

Presentación

08/06/2026

Tipo

OTRO

Zack Debra

Transacción: 08/03/2026

COMPRA

Cambio

+162,311

Precio

Not reported

Presentación

08/06/2026

Tipo

COMPRA

Zack Debra

Transacción: 08/03/2026

COMPRA

Cambio

+324,675

Precio

$1.54

Presentación

08/06/2026

Tipo

COMPRA

Insider	Tipo	Cambio	Precio	Transacción	Presentación
Zack Debra	OTRO	0	Not reported	08/03/2026	08/06/2026
Zack Debra	COMPRA	+162,311	Not reported	08/03/2026	08/06/2026
Zack Debra	COMPRA	+324,675	$1.54	08/03/2026	08/06/2026
Pottage John C Jr	COMPRA	+20,000	$2.15	06/23/2026	06/25/2026
Pottage John C Jr	COMPRA	+10,000	Not reported	06/23/2026	06/25/2026
Jackson Scott Thomas	COMPRA	+20,000	$2.15	06/23/2026	06/25/2026
Jackson Scott Thomas	COMPRA	+10,000	Not reported	06/23/2026	06/25/2026
THOMAS FRANK E	COMPRA	+20,000	$2.15	06/23/2026	06/25/2026
THOMAS FRANK E	COMPRA	+10,000	Not reported	06/23/2026	06/25/2026
VINK PATRICK V.J.J.	COMPRA	+20,000	$2.15	06/23/2026	06/25/2026
VINK PATRICK V.J.J.	COMPRA	+10,000	Not reported	06/23/2026	06/25/2026
Smith Cynthia	COMPRA	+20,000	$2.15	06/23/2026	06/25/2026
Smith Cynthia	COMPRA	+10,000	Not reported	06/23/2026	06/25/2026
Tregoning Kathleen	COMPRA	+20,000	$2.15	06/23/2026	06/25/2026
Tregoning Kathleen	COMPRA	+10,000	Not reported	06/23/2026	06/25/2026
Deshpande Milind	COMPRA	+20,000	$2.15	06/23/2026	06/25/2026
Deshpande Milind	COMPRA	+10,000	Not reported	06/23/2026	06/25/2026
Rajavelu Esther	VENTA	-25,240	$2.51	05/04/2026	05/06/2026
Keutzer Timothy	VENTA	-18,652	$2.36	02/06/2026	02/09/2026
Rajavelu Esther	VENTA	-50,816	$2.36	02/06/2026	02/09/2026

Sobre la compañía

Spero Therapeutics, Inc.

Spero Therapeutics, Inc. is a biopharmaceutical firm in the clinical development stage, primarily focused on discovering, advancing, and commercializing innovative treatments for multi-drug resistant (MDR) bacterial infections and rare diseases within the United States. The company's pipeline includes several key therapeutic candidates: tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic designed to address complicated urinary tract infections (cUTIs), including pyelonephritis, in adult patients. SPR206, an intravenously administered agent specifically developed to combat MDR Gram-negative bacterial infections in hospital environments. SPR720, an oral antibiotic targeting non-tuberculous mycobacterial (NTM) pulmonary disease. Spero Therapeutics has also forged several strategic alliances: A licensing agreement with Meiji Seika Pharma Co., Ltd. supports the ongoing development of tebipenem HBr. A separate licensing deal with Everest Medicines grants rights for the development, manufacturing, and commercialization of SPR206 across Greater China, South Korea, and various Southeast Asian nations. The company collaborates with the Bill & Melinda Gates Medical Research Institute to advance SPR720 for treating lung infections caused by Mycobacterium tuberculosis. Furthermore, a licensing agreement with Vertex Pharmaceuticals Incorporated covers patents associated with SPR720 and its active metabolite, SPR719. Founded in 2013, Spero Therapeutics maintains its corporate headquarters in Cambridge, Massachusetts.

Fuente - Link

Competidores

ABOS ACTU CGTX CRBP HURA INO IRD MCRB SEER VTGN

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

Spero Therapeutics to Participate in the Chardan 10th Annual Healthcare Conference

CAMBRIDGE, Mass., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced that Esther Rajavelu, Spero's President and Chief Executive Officer, will participate in a fireside chat at the Chardan 10th Annual Healthcare Conference to be held in New York City, on October 20th, 2026. Spero's leadership team will also be available for one-on-one meetings at the conference.

GlobeNewsWire

Russian plague outbreak could boost these under-the-radar pharma stocks

Global biosecurity alarms are flashing after an incident at an anti-plague research facility in Siberia sparked a severe public health response. Following the fatal lab exposure of a researcher in Irkutsk region to Yersinia pestis – the bacterium causing pneumonic plague – Russian officials placed several regional hospitals under quarantine and isolated nearly 200 contacts.

Invezz

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced that the Compensation Committee of Spero's Board of Directors approved grants, made on October 1, 2026, of an aggregate of 233,000 restricted stock unit awards (RSUs) and 323,000 stock options to new employees under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, as amended (2019 Inducement Plan). The stock options and RSUs are being granted as an inducement material to Spero's new employees in accordance with Nasdaq Listing Rule 5635(c)(4).

GlobeNewsWire

Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced that the Compensation Committee of Spero's Board of Directors approved a grant, made on September 1, 2026, of an aggregate of 102,000 restricted stock unit awards (RSUs) and 67,600 stock options to new employees under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, as amended (2019 Inducement Plan).

GlobeNewsWire

Spero Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference

CAMBRIDGE, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced that Esther Rajavelu, President and Chief Executive Officer, will present at the H.C.

GlobeNewsWire

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-05-13	-0.18	-0.13	0.05
2026-03-26	-0.2	0.53	0.73
2025-11-13	-0.25	-0.13	0.12
2025-08-12	-0.38	-0.03	0.35
2025-05-13	-0.55	-0.25	0.3
2025-03-27	-0.35	-0.38	-0.03
2024-11-14	-0.27	-0.32	-0.05
2024-08-05	-0.35	-0.33	0.02
2024-05-15	-0.07	-0.24	-0.17
2024-03-13	-0.1	0.96	1.06
2023-11-13	-0.15	0.02	0.17
2023-08-10	-0.29	-0.23	0.06